<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7479474\results\search\testTrace\results.xml">
  <result pre="How does the TB vaccine affect COVID-19? How does one" exact="diagnosis" post="affect the other? Discussions. Few essential elements about TB"/>
  <result pre="coronaviruses) and influenza pandemic/seasonal outbreaks have taught the importance of" exact="infection" post="control to avoid the severe impact on TB patients."/>
  <result pre="between 2012 and 2015, with a threefold increase [4]. Influenza" exact="infection" post="may promote the progression of latent Mycobacterium tuberculosis (MTB)"/>
  <result pre="infection may promote the progression of latent Mycobacterium tuberculosis (MTB)" exact="infection" post="to active TB, alter the clinical presentation of TB,"/>
  <result pre="coinfection with MTB is of particular importance as the TB" exact="diagnosis" post="might be missed or shadowed by concern about COVID-19."/>
  <result pre="TB patients (latent, sequelae, or active) given that current COVID-19" exact="treatment" post="may induce mycobacterial proliferation [14] 3. Methods The electronic"/>
  <result pre="MERS-CoV. The search process included article identification, removing the duplicates," exact="screening" post="titles and abstracts, and assessing eligibility of the selected"/>
  <result pre="vaccine influence COVID-19? (4) How does one condition influence the" exact="diagnosis" post="of the other one? Articles were exported from CORD-19"/>
  <result pre="TB, induction of type I interferons (IFNs) determined by influenza" exact="infection" post="could be detrimental [11], impeding the immune-competent host's ability"/>
  <result pre="host's ability to limit bacterial replication. Thus it promotes the" exact="infection" post="[19] and precipitates TB mortality rate (pneumonia and influenza"/>
  <result pre="severity [20, 21]. One murine model demonstrated that although influenza" exact="infection" post="increased the IFN-Î³ secretion, it had little effect on"/>
  <result pre="further and hospital clusters [22, 23]. Also, inappropriate implementation of" exact="infection" post="control strategies in Singapore led to massive healthcare personnel"/>
  <result pre="infection control strategies in Singapore led to massive healthcare personnel" exact="infection" post="(half of the SARS cases were among healthcare workers)"/>
  <result pre="as a coexisting pathology. In April 2003, a SARS-related hospital" exact="screening" post="from Taipei (Taiwan) resulted in discovering 60â€‰TB cases among"/>
  <result pre="mice regarding the suppression of cellular immunity after a viral" exact="infection" post="[11]. There is also data on MERS-CoV augmenting TB"/>
  <result pre="decrease the opportunity of SARS-CoV-2 spreading among TB cases, hospital" exact="treatment" post="for TB patients should be limited to severe cases."/>
  <result pre="to the one of SARS-CoV-1. Substantial evidence suggests that SARS-CoV-2" exact="infection" post="could initiate an aggressive inflammation by increasing cytokines secretion"/>
  <result pre="cohort of 49 patients with active TB and COVID-19, the" exact="diagnosis" post="of COVID-19 preceded or was simultaneous (within seven days)"/>
  <result pre="with TB in 23 patients, raising the suspicion that SARS-CoV-2" exact="infection" post="might boost the development of active TB. However, this"/>
  <result pre="However, this remains purely speculative as individuals with latent TB" exact="infection" post="were not followed up over time [30]. Cytokines have"/>
  <result pre="host resistance to TB infection, being first demonstrated in murine" exact="infection" post="models [19] and later validated by severe mycobacterial disease"/>
  <result pre="31]. Since the SARS-CoV-2 is a newly discovered pathogen (first" exact="infection" post="being reported in December 2019) [29], little data about"/>
  <result pre="of contracting influenza or SARS might also have a higher" exact="prevalence" post="of MTB [38]. It is no coincidence that the"/>
  <result pre="Another serious problem posed by the COVID-19 pandemic is the" exact="treatment" post="continuity of TB patients. The nature of the disease,"/>
  <result pre="of TB patients. The nature of the disease, with extended" exact="treatment" post="regimens and poor outcomes with drug resistance resulting from"/>
  <result pre="the more in a pandemic context with numerous and stringent" exact="isolation" post="measures [40]. This shifts the directly observed therapy to"/>
  <result pre="in mind that the United States delayed the implementation of" exact="infection" post="control strategies (that could avoid superspreading events). There still"/>
  <result pre="healthcare workers' BCG vaccination will have any impact on SARS-CoV-2" exact="infection" post="(BCG Vaccination to Protect Healthcare Workers against COVID-19, BRACE,"/>
  <result pre="based on S protein are also considered for preventing SARS-CoV-2" exact="infection" post="[47, 58, 59]. Novel methods are emerging such as"/>
  <result pre="the interferon-gamma release assays (IGRAs) are widely used for TB" exact="screening" post="[63]. Given their results are influenced by the host's"/>
  <result pre="an impaired immune system, such as in a concurrent severe" exact="infection" post="[65, 66]. Increased age, low peripheral lymphocyte count, high"/>
  <result pre="for a few months in humans, there is no specific" exact="treatment" post="[13]. Given the growing number of reported cases, suspected"/>
  <result pre="detecting viral antigens or antiviral antibodies and newer methods of" exact="diagnosis" post="as multiplex nucleic acid amplification have been developed and"/>
  <result pre="the SARS-CoV-2 pandemic, countries struggled to quickly find a possible" exact="treatment" post="to prevent respiratory failures and deaths, especially among patients"/>
  <result pre="carry out new drug development in the traditional manner. Therefore," exact="screening" post="for already available drugs (for any activity against SARS-CoV-2)"/>
  <result pre="It seems to have entered as a recommendation in the" exact="treatment" post="of the COVID-19 in a short time [13]. Other"/>
  <result pre="been associated with a higher risk of nontuberculous mycobacterial (NTM)" exact="infection" post="in rheumatoid arthritis patients [14]. 4.4.1. Key Points Coinfection"/>
  <result pre="of TB and SARS-CoV-2 may be challenging to diagnose. SARS-CoV-2" exact="infection" post="may mask the clinical and radiological active TB. Patients"/>
  <result pre="the clinical and radiological active TB. Patients receiving the proposed" exact="treatment" post="for COVID-19 may be at risk for the infection"/>
  <result pre="proposed treatment for COVID-19 may be at risk for the" exact="infection" post="with NTM. 5. Conclusions Because viral respiratory infections and"/>
  <result pre="of tuberculosis reactivation. As a lesson from previous outbreaks, hospital" exact="treatment" post="for patients with tuberculosis should be limited to severe"/>
  <result pre="a systematic reviewInfluenza and Other Respiratory Viruses2020141779110.1111/irv.1267031568678 7SmallC.-L.ShalerC. R.McCormickS.et al.Influenza" exact="infection" post="leads to increased susceptibility to subsequent bacterial superinfection by"/>
  <result pre="lipid mediator networks in tuberculosisImmunological Reviews2015264126427510.1111/imr.1224925703565 20RothS.WhiteheadS.ThamthitiwatS.et al.Concurrent influenza virus" exact="infection" post="and tuberculosis in patients hospitalized with respiratory illness in"/>
  <result pre="of Infectious Diseases2004189464865110.1086/38153514767818 27Nosocomial transmission of Mycobacterium tuberculosis found through" exact="screening" post="for severe acute respiratory syndromeâ€&quot;Taipei, Taiwan, 2003MMWR Morbidity and"/>
  <result pre="East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: implications for" exact="infection" post="controlIntervirology2017601-2535510.1159/00047790828683463 29GuanW. J.NiZ. Y.HuY.LiangW. H.OuC. Q.HeJ. X.Clinical characteristics of"/>
  <result pre="the National Academy of Sciences201210943173171731810.1073/pnas.1215761109 52Hollm-DelgadoM.-G.StuartE. A.BlackR. E.Acute lower respiratory" exact="infection" post="among Bacille Calmette-GuÃ©rin (BCG)-vaccinated childrenPediatrics20141331e73e8110.1542/peds.2013-221824379224 53PollardA. J.FinnA.CurtisN.Non-specific effects of"/>
  <result pre="studyPLoS One201510610.1371/journal.pone.0129792 68ZhangW.ZhaoY.ZhangF.et al.The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
 </snippets>
</snippetsTree>
